Quest PharmaTech Management
Management criteria checks 3/4
Quest PharmaTech's CEO is Madi Madiyalakan, appointed in Aug 2006, has a tenure of 18.17 years. total yearly compensation is CA$390.00K, comprised of 64.1% salary and 35.9% bonuses, including company stock and options. directly owns 1.89% of the company’s shares, worth $69.76K. The average tenure of the management team and the board of directors is 19.9 years and 14.3 years respectively.
Key information
Madi Madiyalakan
Chief executive officer
CA$390.0k
Total compensation
| CEO salary percentage | 64.1% |
| CEO tenure | 18.2yrs |
| CEO ownership | 1.9% |
| Management average tenure | 19.9yrs |
| Board average tenure | 14.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -CA$3m |
| Apr 30 2024 | n/a | n/a | -CA$4m |
| Jan 31 2024 | CA$390k | CA$250k | -CA$3m |
| Oct 31 2023 | n/a | n/a | -CA$65m |
| Jul 31 2023 | n/a | n/a | -CA$64m |
| Apr 30 2023 | n/a | n/a | -CA$64m |
| Jan 31 2023 | CA$269k | CA$215k | -CA$65m |
| Oct 31 2022 | n/a | n/a | -CA$78m |
| Jul 31 2022 | n/a | n/a | -CA$87m |
| Apr 30 2022 | n/a | n/a | -CA$86m |
| Jan 31 2022 | CA$189k | CA$40k | -CA$85m |
| Oct 31 2021 | n/a | n/a | CA$68m |
| Jul 31 2021 | n/a | n/a | CA$81m |
| Apr 30 2021 | n/a | n/a | CA$83m |
| Jan 31 2021 | CA$270k | CA$40k | CA$190m |
| Oct 31 2020 | n/a | n/a | CA$111m |
| Jul 31 2020 | n/a | n/a | CA$106m |
| Apr 30 2020 | n/a | n/a | CA$102m |
| Jan 31 2020 | n/a | n/a | -CA$6m |
| Oct 31 2019 | n/a | n/a | -CA$5m |
| Jul 31 2019 | n/a | n/a | -CA$5m |
| Apr 30 2019 | n/a | n/a | -CA$5m |
| Jan 31 2019 | CA$105k | CA$30k | -CA$4m |
| Oct 31 2018 | n/a | n/a | -CA$5m |
| Jul 31 2018 | n/a | n/a | -CA$6m |
| Apr 30 2018 | n/a | n/a | -CA$5m |
| Jan 31 2018 | CA$127k | CA$26k | -CA$5m |
Compensation vs Market: Madi's total compensation ($USD283.39K) is below average for companies of similar size in the US market ($USD679.79K).
Compensation vs Earnings: Madi's compensation has increased whilst the company is unprofitable.
CEO
Madi Madiyalakan
18.2yrs
Tenure
CA$390,000
Compensation
Dr. Ragupathy Madiyalakan, Ph D., also known as Madi, serves as Chief Executive Officer at OncoQuest Inc. He has been the Chief Executive Officer of Quest PharmaTech, Inc. since August 2006. Dr. Madiyalaka...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 18.2yrs | CA$390.00k | 1.89% $ 69.8k | |
| Chief Financial Officer | 19.8yrs | CA$118.17k | 1.08% $ 39.9k | |
| Head of Investor Relations & Corporate Communications | 20yrs | no data | no data | |
| Vice President of Corporate Development | no data | CA$37.94k | no data | |
| Vice President of Product Development | 22.3yrs | CA$15.00k | no data |
19.9yrs
Average Tenure
Experienced Management: QPTF.F's management team is seasoned and experienced (19.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 20.3yrs | CA$390.00k | 1.89% $ 69.8k | |
| Independent Chairman | 3.3yrs | CA$34.00k | no data | |
| Member of Scientific Advisory Board | 19.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 19.2yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 14.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.3yrs | CA$26.00k | 0.21% $ 7.6k | |
| Independent Director | less than a year | no data | no data |
14.3yrs
Average Tenure
Experienced Board: QPTF.F's board of directors are seasoned and experienced ( 14.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/12 03:03 |
| End of Day Share Price | 2024/07/15 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2024/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Quest PharmaTech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|